Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 2
2(66.7%)
Phase 1
1(33.3%)
3Total
Phase 2(2)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT04274283Recruiting

Tessa Jowell BRAIN MATRIX - Platform Study

Role: collaborator

NCT05629702Phase 2Recruiting

ARISTOCRAT: Blinded Trial of Temozolomide +/- Cannabinoids

Role: collaborator

NCT02768337Phase 1Terminated

Cambridge Brain Mets Trial 1

Role: collaborator

NCT02147028Phase 2Completed

Hippocampal Sparing Whole Brain Radiotherapy vs Conventional Whole Brain Radiotherapy in Patients With Brain Metastases

Role: collaborator

All 4 trials loaded